Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

The Role of Cyclooxygenase Inhibitors in Cancer Prevention

Author(s): William F. Anderson, Asad Umar, Jaye L. Viner and Ernest T. Hawk

Volume 8, Issue 12, 2002

Page: [1035 - 1062] Pages: 28

DOI: 10.2174/1381612023394935

Price: $65

Abstract

Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institutes (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.

Keywords: mf-tricyclio, colorectal carcinogenesis, apc, nin


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy